{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not reached due to fewer number of participants with event.","groupId":"OG000","lowerLimit":"1.4","upperLimit":"NA","value":"2.8"},{"comment":"Upper limit of 95% CI was not reached due to fewer number of participants with event.","groupId":"OG001","lowerLimit":"2.7","upperLimit":"NA","value":"2.8"},{"comment":"Upper limit of 95% CI was not reached due to fewer number of participants with event.","groupId":"OG002","lowerLimit":"1.9","upperLimit":"NA","value":"3.8"},{"comment":"Upper limit of 95% CI was not reached due to fewer number of participants with event.","groupId":"OG003","lowerLimit":"1.5","upperLimit":"NA","value":"1.6"},{"groupId":"OG004","lowerLimit":"1.4","upperLimit":"3.5","value":"1.8"},{"comment":"Upper limit of 95% CI was not reached due to fewer number of participants with event.","groupId":"OG005","lowerLimit":"0.9","upperLimit":"NA","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause, or censoring, whichever occurred first. Both new anti-cancer therapy given prior to PD or death and no PD by the end of follow-up are censoring events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 1 mg as a subcutaneous (SC) administration every 2 weeks (Q2W) for a maximum duration of 10.9 months.","id":"OG000","title":"PF-07209960 1 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 3 mg as a SC administration Q2W for a maximum duration of 5.1 months.","id":"OG001","title":"PF-07209960 3 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 10 mg as a SC administration Q2W for a maximum duration of 3.4 months.","id":"OG002","title":"PF-07209960 10 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 15 mg as a SC administration Q2W for a maximum duration of 5.8 months.","id":"OG003","title":"PF-07209960 15 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.","id":"OG004","title":"PF-07209960 20 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.","id":"OG005","title":"PF-07209960 30 mg SC"}],"paramType":"MEDIAN","populationDescription":"The full analysis set includes all enrolled participants.","reportingStatus":"POSTED","timeFrame":"Baseline through up to 2 years or until disease progression","title":"Progression-Free Survival (PFS) Based on Investigator Assessment in Participants","type":"SECONDARY","unitOfMeasure":"Months"}